AYTU - Company ID 0001385818
The table below shows AYTU BIOPHARMA, INC's income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $66.38M | $65.18M | $107.40M | $96.67M | $65.63M | $27.63M |
| Cost of revenue | $20.55M | $16.13M | $40.77M | $44.39M | $36.43M | $8.28M |
| Gross profit | $45.83M | $49.05M | $66.63M | $52.28M | $29.20M | $19.35M |
| R&D | $1.33M | $2.77M | $4.09M | $12.66M | $5.62M | $1.72M |
AYTU BIOPHARMA, INC reported annual revenue of $66.38M for fiscal year 2025. That is up 1.8% from $65.18M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $2.56M (FY 2016) to $66.38M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $17.38M |
| $19.95M |
| $28.63M |
| $31.17M |
| $25.50M |
| $34.80M |
| Operating income | -$7.83M | -$1.59M | -$17.07M | -$109.91M | -$58.87M | -$21.13M |
| Income tax | $437.00K | $2.14M | $0.00 | -$110.00K | $259.00K | $0.00 |
| Net income | -$13.56M | -$15.84M | -$17.05M | -$108.78M | -$58.29M | -$13.62M |
| EPS (diluted) | - | - | -$5.11 | -$74.01 | -$3.48 | - |